{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:24:25Z","timestamp":1792920265570,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jcmgh.2020.10.010","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:39:19Z","timestamp":1603489159000},"page":"739-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice"],"prefix":"10.1016","volume":"11","author":[{"given":"Kyo","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohji","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-1720","authenticated-orcid":false,"given":"Keisuke","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2020.10.010_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2016.11.020","article-title":"Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012","volume":"152","author":"White","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A\u00a0meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a radomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrc2817","article-title":"Targeting metabolic transformation for cancer therapy","volume":"10","author":"Tennant","year":"2010","journal-title":"Nat Rev cancer"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib6","first-page":"317","article-title":"Metabolism of tumors","volume":"142","author":"Warburg","year":"1923","journal-title":"Biochem Zeitschr"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased tumor glycolysis characterizes immune resistance to adaptive T cells therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A\u00a0phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/pros.21172","article-title":"Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies","volume":"70","author":"Stein","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vascular for treatment of cancer and other disease","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib14","first-page":"6387","article-title":"A\u00a0new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/micc.12228","article-title":"A\u00a0retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects","volume":"23","author":"Maeda","year":"2016","journal-title":"Microcirculation"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib18","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.2147\/IJN.S147668","article-title":"Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting","volume":"12","author":"Park","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib19","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.3390\/cancers12030615","article-title":"Haprolid inhibits tumor growth of hepatocellular carcinoma through Rb\/E2F and Akt\/mTOR inhibition","volume":"12","author":"Xing","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/039463201202500412","article-title":"Combined blockade of Akt\/mTOR pathway inhibits growth of human hemangioma via downregulation of proliferating cell nuclear antigen","volume":"25","author":"Ou","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib21","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.onc.1210715","article-title":"Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1","volume":"27","author":"Averous","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib22","doi-asserted-by":"crossref","first-page":"53269","DOI":"10.18632\/oncotarget.10756","article-title":"The mTOR\/AP-1\/VEGF signaling pathway regulates vascular endothelial cell growth","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2014.09.003","article-title":"2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy","volume":"355","author":"Zhang","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib25","article-title":"The regulation of inflammation by interferons and their STATs","volume":"2","author":"Rauch","year":"2013","journal-title":"JAKSTAT"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","article-title":"Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function","volume":"69","author":"Wan","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib30","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.0801124","article-title":"NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment","volume":"182","author":"Mailloux","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1148\/radiol.2382041977","article-title":"Integrated PET\/CT: current applications and future directions","volume":"238","author":"Von Schulthess","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1478-3231.2011.02541.x","article-title":"Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib","volume":"31","author":"Lee","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib34","doi-asserted-by":"crossref","first-page":"30412","DOI":"10.1074\/jbc.272.48.30412","article-title":"Interaction of NF-kappaB and NFAT with the interferon-gamma promoter","volume":"272","author":"Sica","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib35","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/eji.200838289","article-title":"Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+T cells","volume":"38","author":"Cham","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib36","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib38","first-page":"485","article-title":"Certain metabolic and pharmacological effects in cancer patients given infusions of 2-deoxy-D-glucose","volume":"21","author":"Landau","year":"1958","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.110.157032","article-title":"Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension","volume":"57","author":"Chen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib40","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Barreira da Silva","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice","volume":"7","author":"Nishina","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2007.10.011","article-title":"Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription","volume":"134","author":"Nishina","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib43","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3 expressing CD4+\/CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2003.07.008","article-title":"A\u00a0novel optic assay for the quantitative measurement of chemotaxis","volume":"282","author":"Kanegasaki","year":"2003","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jcmgh.2020.10.010_bib45","first-page":"404","article-title":"Systematic single cell analysis of migration and morphological changes of human neutrophils over stimulus concentration gradients","author":"Yamauchi","year":"2014","journal-title":"J\u00a0Immunol Methods"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:26:52Z","timestamp":1762453612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X20301739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["S2352345X20301739"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.10.010","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}